Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients
Authors:
- Nerina C van der MerweNMNerina C van der Merwe
- Ines BuccimazzaIBInes Buccimazza
- Bianca RossouwBRBianca Rossouw
- Monica AraujoMAMonica Araujo
- Kholiwe S NtaitaKNKholiwe S Ntaita
- Mardelle SchoemanMSMardelle Schoeman
- Karin VorsterKVKarin Vorster
- Kgabo NapoKNKgabo Napo
- Maritha J KotzeMKMaritha J Kotze
- Jaco OosthuizenJOJaco Oosthuizen
Open Access
- 30 May 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 207 (2) , 331-342
Abstract
Purpose: Genetically predisposed breast cancer (BC) patients represent a minor but clinically meaningful subgroup of the disease, with 25% of all cases associated with actionable variants in BRCA1/2. Diagnostic implementation of next-generation sequencing (NGS) resulted in the rare identification of BC patients with double heterozygosity for deleterious variants in genes partaking in homologous recombination repair of DNA. As clinical heterogeneity poses challenges for genetic counseling, this study focused on the occurrence and clinical relevance of double heterozygous BC in South Africa. Methods: DNA samples were diagnostically screened using the NGS-based Oncomine™ BRCA Expanded Research Assay. Data was generated on the Ion GeneStudio S5 system and analyzed using the Torrent Suite™ and reporter software. The clinical significance of the variants detected was determined using international variant classification guidelines and treatment implications. Results: Six of 1600 BC patients (0.375%) tested were identified as being bi-allelic for two germline likely pathogenic or pathogenic variants. Most of the variants were present in BRCA1/2, including two founder-related small deletions in three cases, with family-specific variants detected in ATM, BARD1, FANCD2, NBN, and TP53. The scientific interpretation and clinical relevance were based on the clinical and tumor characteristics of each case. Conclusion: This study increased current knowledge of the risk implications associated with the co-occurrence of more than one pathogenic variant in the BC susceptibility genes, confirmed to be a rare condition in South Africa. Further molecular pathology-based studies are warranted to determine whether clinical decision-making is affected by the detection of a second pathogenic variant in BRCA1/2 and TP53 carriers.Keywords
Funding Information
- University of the Free State
This publication has 84 references indexed in Scilit:
- A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancerJournal of Cancer Research and Clinical Oncology, 2023
- Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implicationsBreast Cancer Research and Treatment, 2021
- New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IVHuman Mutation, 2020
- Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianCancer, 2014
- Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer riskTumor Biology, 2013
- A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genesBreast Cancer, 2012
- I171V germline mutation in the NBS1 gene significantly increases risk of breast cancerBreast Cancer Research and Treatment, 2007
- Loss of expression of FANCD2 protein in sporadic and hereditary breast cancerBreast Cancer Research and Treatment, 2007
- DNA Interstrand Crosslinks: Natural and Drug‐Induced DNA Adducts that Induce Unique Cellular ResponsesChemBioChem, 2005
- BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner familiesInternational Journal of Cancer, 2004